These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 670902)

  • 1. [Endogenous 3-O-methyldopa in man: normal level and effect of an inhibitor of aromatic amino-acid decarboxylase (Benserazid) (author's transl)].
    Geissbühler F; Raffin Y; Combépine C; Streiff U; Hovaguimian T
    J Clin Chem Clin Biochem; 1978 Jun; 16(6):355-8. PubMed ID: 670902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Urinary excretion of 3,4-dihydroxyphenyl-alanine, 3-O-methyldopa, dopamine and homovanillic acid in man. Effects of an inhibitor of decarboxylase of aromatic amino acids (Benserazide) (author's transl)].
    Geissbühler F; Widmer J
    J Clin Chem Clin Biochem; 1976 Nov; 14(11):543-7. PubMed ID: 1003116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
    Puca FM; Megna GF; Masi G; Specchio LM
    Riv Patol Nerv Ment; 1974 Oct; 95(5):676-84. PubMed ID: 4470268
    [No Abstract]   [Full Text] [Related]  

  • 4. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
    Boomsma F; Meerwaldt JD; Man in 't Veld AJ; Hovestadt A; Schalekamp MA
    Ann Neurol; 1989 Jun; 25(6):624-8. PubMed ID: 2742363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Variation in the pharmacologic affects of decarboxylase inhibitor in variable doses in man].
    Castaigne P; Rondot P; Taberlet A; Baumann N
    Biomedicine; 1974 Dec; 21(12):486-90. PubMed ID: 4462871
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of different dopa decarboxylase inhibitors on the hypotensive response to alpha-methyldopa in rats.
    Henning M
    Br J Pharmacol; 1968 Sep; 34(1):233P-234P. PubMed ID: 5676035
    [No Abstract]   [Full Text] [Related]  

  • 7. Aromatic amino acid decarboxylase inhibitors.
    Porter CC
    Fed Proc; 1971; 30(3):871-6. PubMed ID: 5575298
    [No Abstract]   [Full Text] [Related]  

  • 8. [Action of a peripheral inhibitor of dopa-decarboxylase on the inhibition by L-DOPA of the hypothalamo-hypophyseo-adrenocortical system in man].
    Balestreri R; Bertolini S; Elicio N; Costa S
    Boll Soc Ital Biol Sper; 1974 Jul; 50(12):832-7. PubMed ID: 4447697
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapy of parkinsonian syndromes and plasmatic DOPA levels. Effects of L-DOPA and 3-OMD, administered alone or combined, with or without a decarboxylase inhibitor].
    Geissbühler F; Gaillard JM; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Rev Eur Etud Clin Biol; 1972 Jan; 17(1):38-44. PubMed ID: 5041348
    [No Abstract]   [Full Text] [Related]  

  • 10. Reduction of aromatic L-amino acid decarboxylase protein in rats after chronic administration of alpha-methyldopa.
    Culvenor AJ; Jarrott B
    Mol Pharmacol; 1979 Jan; 15(1):86-98. PubMed ID: 106235
    [No Abstract]   [Full Text] [Related]  

  • 11. [Research on the inhibitory action of several salicylic chalcones on the aromatic L-aminoacid-decarboxylase].
    Lesieur-Demarquilly I; Mizon J; Osteux R
    Ann Pharm Fr; 1973 Nov; 31(11):705-8. PubMed ID: 4794659
    [No Abstract]   [Full Text] [Related]  

  • 12. Peripheral aromatic L-amino acids decarboxylase inhibitor in Parkinsonism. I. Effect on O-methylated metabolites of L-dopa-2- 14 C.
    Messiha FS; Hsu TH; Bianchine JR
    J Clin Invest; 1972 Feb; 51(2):452-5. PubMed ID: 5009125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [EFFECT OF ALPHA-METHYLDOPALANINE AND SERYLTRIHYDROXYBENZYLHYDRAZINE (RO 4-4602) ON THE DOPA-DECARBOXYLASE ACTIVITY].
    CHRUSCIEL TL; POJDA SM
    Acta Physiol Pol; 1965; 16():111-5. PubMed ID: 14338596
    [No Abstract]   [Full Text] [Related]  

  • 14. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
    Rabadeau Dumas JL; Rondot P; Cardon P
    Therapie; 1977; 32(2):161-72. PubMed ID: 898124
    [No Abstract]   [Full Text] [Related]  

  • 15. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
    Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
    Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of L-5-hydroxytryptophan alone and in combination with a decarboxylase inhibitor (Ro-4-4602) in depressive patients.
    Matussek N; Angst J; Benkert O; Gmür M; Papousek M; Rüther E; Woggon B
    Adv Biochem Psychopharmacol; 1974; 11(0):399-404. PubMed ID: 4602669
    [No Abstract]   [Full Text] [Related]  

  • 17. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P
    Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of DOPA decarboxylase by the hydrazino analog of alpha-methylDOPA.
    PORTER CC; WATSON LS; TITUS DC; TOTARO JA; BYER SS
    Biochem Pharmacol; 1962 Nov; 11():1067-77. PubMed ID: 13972347
    [No Abstract]   [Full Text] [Related]  

  • 19. The mode of action of -methyldopa.
    Day MD; Roach AG; Whiting RL
    Br J Pharmacol; 1972 May; 45(1):168P-169P. PubMed ID: 5041485
    [No Abstract]   [Full Text] [Related]  

  • 20. POTENT DECARBOXYLASE INHIBITORS. ANALOGS OF METHYLDOPA.
    SLETZINGER M; CHEMERDA JM; BOLLINGER FW
    J Med Chem; 1963 Mar; 6():101-3. PubMed ID: 14188777
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.